Catalog No.
Product Name
Application
Product Information
Citations
-
κ-Opioid Receptor Agonist
R-84760 is a selective κ-opioid receptor agonist that exhibits significant antinociceptive effects. This compound is primarily utilized in pain research, offering insights into the modulation of pain pathways and potential therapeutic applications in analgesia. Its specificity for the κ-opioid receptor makes it a valuable tool for understanding opioid receptor pharmacology and the development of new pain management strategies. -
Opioid Compound
N-Phenethylnoroxymorphone is an opioid compound that acts primarily on the μ-opioid receptor, enhancing the analgesic effects of morphine. This compound has demonstrated increased morphine-induced analgesia in preclinical models, particularly in rats. Its potent efficacy makes it suitable for research applications in the study of pain mechanisms and neurological disorders. -
Opioid Compound
Dipyanone hydrochloride is an opioid compound that interacts with the mu-opioid receptor, leading to analgesic effects. This reagent is primarily used in research related to pain management and opioid receptor studies. Its structural similarity to other opioids makes it a valuable tool for investigating opioid mechanisms and exploring potential therapeutic applications. -
μ-Opioid Receptor Agonist
U-48520 is a μ-opioid receptor agonist, demonstrating an EC50 value of 1561 nM. This compound is primarily utilized in research applications focused on pain management and opioid signaling pathways. Its activity at the μ-opioid receptor underscores its potential for studying analgesic effects and receptor pharmacodynamics in cellular and in vivo models. -
Opioid Receptor Antagonist
JTC-801 free base is a selective antagonist of the opioid receptor-like 1 (ORL1) receptor, exhibiting a binding affinity with a Ki value of 8.2 nM. This compound effectively modulates ORL1 receptor signaling, making it a valuable tool for research into pain modulation and opioid receptor pharmacology. Its application extends toward studying the role of ORL1 in various physiological and pathological processes. -
Opioid Compound
Bromadol is a synthetic opioid that acts as a potent agonist at the mu-opioid receptor. It exhibits significant analgesic properties, making it valuable for pain research and pharmacological studies. Bromadol's unique chemical structure offers potential insights into opioid receptor mechanisms and the development of novel analgesics. -
Opioid Compounds
AH 7563 is an opioid compound that demonstrates significant analgesic properties. In in vivo assays, it exhibited an ED50 of 15.3 mg/kg when administered orally and 15.5 mg/kg via subcutaneous injection, as measured in the phenylquinone and hot plate tests in mice. This compound is suitable for research applications focusing on pain management and opioid receptor studies. -
Opioid Compound
N-(1-Phenethyl-4-piperidyl)-N-phenethylpropanamide hydrochloride is an opioid compound that acts primarily on the opioid receptors in the central nervous system. This compound demonstrates significant analgesic properties and is useful in studies exploring pain relief mechanisms. It is applicable in research focusing on opioid receptor modulation and the development of new therapeutic agents for pain management. -
Opioid Compound
3,4-Ethylenedioxy U-51754 hydrochloride is an opioid compound that acts primarily on the opioid receptors in the central nervous system. It exhibits analgesic properties and is utilized in research focused on pain modulation and the development of new analgesics. This reagent is essential for studies investigating the structure-activity relationships of opioid analogs and their potential therapeutic effects. -
κ-opioid receptor Antagonist
5′-Guanidinonaltrindole is a selective antagonist of the κ-opioid receptor, inhibiting its activation. This compound plays a crucial role in research related to pain modulation, stress response, and addiction mechanisms. It is instrumental in studying the physiological effects and potential therapeutic applications of kappa opioid receptor modulation in various biological systems. -
Opioid Compound
3,4-Difluoro-N-desmethyl U-47700 hydrochloride is an opioid compound that acts on the μ-opioid receptor, demonstrating potent analgesic properties. This reagent is primarily utilized in research focused on pain management and addiction studies, contributing to a deeper understanding of opioid receptor activities and their therapeutic implications. Its unique fluorinated structure enhances its pharmacological profile, making it a valuable tool for scientific investigations into opioid-related pathways. -
Opioid Analog
Chlorphine is a halogenated opioid analog that primarily targets opioid receptors in the central nervous system. This compound exhibits significant neuroactive properties, making it valuable for studying pain modulation and addiction mechanisms. Its unique structure allows for exploration of receptor interactions and the development of potential therapeutic agents in pain management and opioid research. -
Opioid Receptor
3,4-Difluoro U-49900 hydrochloride is a selective opioid receptor agonist, primarily targeting the mu-opioid receptor. This compound exhibits strong analgesic properties and is utilized in research to investigate opioid signaling pathways and pain management mechanisms. Its potential applications include studies on addiction, analgesia, and opioid receptor pharmacology. -
Opioid Compound
Desmethylmoramide is an opioid compound that exerts its effects primarily through interaction with opioid receptors, facilitating pain relief. This compound demonstrates notable analgesic activity in rodent models, making it a valuable tool for research into pain management and opioid pharmacology. Its structural similarity to established opioids may provide insights into opioid receptor function and the development of new analgesic therapies. -
Opioid Receptor
DuP 747 hydrochloride is a selective agonist of the kappa-opioid receptor, primarily involved in analgesic activity. Studies indicate its administration can yield variable responses, with a lesser agonistic profile when given subcutaneously compared to intraperitoneal or oral routes. Notably, the 5-hydroxy-desmethoxy metabolite of DuP 747 predominantly influences behaviors associated with the saline-appropriate lever. These findings highlight the potential role of its metabolites in mediating responses similar to other kappa-opioid receptor ligands, enabling further exploration in the field of pain management and receptor pharmacology. -
Opioid Compound
Ortho-methyl 4-anilino-1-boc-piperidine is an opioid compound that serves as a crucial precursor in synthetic pathways for the development of opioid receptor ligands. This reagent is valuable in chemical research aimed at designing and optimizing new analgesics with potential therapeutic applications in pain management and addiction treatment. Its structural features allow for modifications that can lead to enhanced receptor selectivity and activity. -
Opioid Receptor
CP-866,087 is a potent and selective μ-opioid receptor antagonist. It effectively inhibits opioid effects and has demonstrated promising preclinical efficacy in models related to alcohol consumption. Additionally, CP-866,087 has been utilized in research investigating female sexual dysfunction. -
Opioid Compound
Orphine is an opioid compound that primarily targets the opioid receptors in the central nervous system. It has been shown to enhance antinociceptive effects in murine models, with these effects being reversed by Naloxone, indicating its potential utility in pain management research. This compound is valuable for studying opioid mechanisms and developing analgesic therapies. -
Opioid Compound
AH 8529 is an orally active opioid compound that primarily targets opioid receptors. It exhibits potent analgesic activity, making it valuable for pain management research. Its unique pharmacological profile enables investigations into opioid receptor signaling and the development of novel pain therapeutics. -
Opioid Compound
N-(1-Benzyl-4-piperidyl)-N-benzylpropanamide hydrochloride is an opioid compound that interacts with opioid receptors, primarily influencing the mu-opioid receptor pathway. This compound exhibits significant analgesic properties, making it a valuable tool for research focused on pain management and opioid receptor characterization. Its unique structure provides a basis for exploring potential leads in the development of novel analgesics. -
Opioid Compound
2,4-Difluoro U-48800 hydrochloride is a selective u-opioid receptor agonist. It exhibits significant analgesic properties, making it valuable in pain management research. This compound is useful for studying opioid receptor interactions and the development of novel analgesics in medicinal chemistry. -
Opioid Compound
Methylketobemidone is an opioid receptor agonist that interacts primarily with the mu-opioid receptor. This compound exhibits significant analgesic activity, making it a valuable tool for investigating pain pathways and developing pain management therapies. Its structural similarity to existing opioids allows for comparative studies in opioid receptor pharmacology and the evaluation of potential side effects and efficacy in preclinical research. -
Opioid Compound
3,4-Difluoro U-50488 hydrochloride is a selective kappa-opioid receptor agonist. This compound exhibits potent analgesic activity and has been utilized in research to explore the neuropharmacological effects of kappa-opioid receptor modulation. Its unique structural modifications enhance specificity, making it a valuable tool for investigating pain pathways and opioid signaling mechanisms in various biological contexts. -
Opioid Compound
2-Naphthyl U-47700 is a selective μ-opioid receptor agonist. It demonstrates potent analgesic activity, making it an important compound for research into pain management and opioid receptor functionality. This reagent is useful for exploring the pharmacological effects of opioids and investigating potential therapeutic applications in pain relief. -
Opioid Compounds
AH 8507 is an analog of AH 7563, belonging to the class of opioid compounds. Despite its structural similarity, AH 8507 displays minimal analgesic effects in animal models, with ED50 values exceeding 100 mg/kg in both the phenylquinone and hot plate tests. This compound is primarily utilized in research to further understand the mechanisms of opioid activity and to explore the structure-activity relationship within opioid analogs. -
Opioid Compound
3,4-Difluoro propyl U-47700 is an opioid compound that acts as a selective agonist at the mu-opioid receptor. This compound exhibits potent analgesic properties and is primarily utilized in pharmacological research related to pain management and opioid receptor studies. Its structural modifications enhance its biological activity, making it a valuable tool for understanding opioid mechanisms and potential therapeutic applications. -
Opioid Receptor Modulator
Samidorphan hydrochloride is an opioid receptor modulator with significant binding affinity for μ-opioid, κ-opioid, and δ-opioid receptors. It functions primarily as an antagonist at μ-opioid receptors while acting as a partial agonist at κ- and δ-opioid receptors. This unique profile enables Samidorphan hydrochloride to modulate opioid activity, making it a valuable tool in research focused on depression and other mood disorders. Its ability to improve behavioral outcomes in depressed animal models highlights its potential applications in neuropharmacology. -
Opioid Compound
3,4-Difluoro isopropyl U-47700 is a synthetic opioid compound that acts primarily on the mu-opioid receptor. It exhibits potent analgesic effects, making it relevant for research into pain management and opioid receptor pharmacology. Its unique structure allows for the exploration of opioid effects as well as potential applications in the study of drug interactions and addiction mechanisms. -
Opioid Compound
U-49900 is a u-opioid receptor agonist that demonstrates significant analgesic properties. Its primary mechanism involves modulating pain responses by activating the u-opioid receptor, which is integral in the management of pain signaling pathways. This compound is commonly used in pharmacological studies focusing on pain relief, opioid receptor interactions, and the development of novel analgesics. -
Opioid Receptor Agonist
Salvinorin A carbamate is a potent κ-opioid receptor agonist, exhibiting an EC50 value of 6.2 nM and a Ki of 3.2 nM. This compound demonstrates significant biological activity in modulating pain and has potential applications in the study of addiction and mood disorders. Its unique pharmacological profile makes it a valuable tool for research in opioid receptor signaling and therapeutic development. -
Opioid Compound
Bipiperidinyl 4-ANPP is an opioid compound that interacts primarily with the mu-opioid receptor. This compound demonstrates significant analgesic properties and is utilized in research focused on pain management and opioid receptor pharmacology. Its structural similarity to known opioids positions it as a valuable tool for investigating the mechanisms underlying opioid action and potential therapeutic applications in chronic pain and addiction studies. -
μ-Opioid Receptor Agonist
Endomorphin 2 is a high-affinity agonist of the μ-opioid receptor, exhibiting selectivity and potency in targeting this pathway. It also shows moderate affinity for kappa3 binding sites, with a Ki value ranging from 20 to 30 nM. This compound is valuable for research in pain management, neurobiology, and the pharmacological characterization of opioid receptors. Its unique properties make it suitable for studies focused on opioid signaling and potential therapeutic applications in pain relief. -
MCH1 receptor Antagonist
RGH-706 is a selective MCH1 receptor antagonist with an IC50 of 6.2 nM against human MCHR1, demonstrating oral bioavailability and the ability to cross the blood-brain barrier. This compound is primarily utilized in research focused on obesity and Prader-Willi syndrome, as it effectively improves obesity-related outcomes without antagonizing hMCH2 receptors. RGH-706 serves as a valuable tool for studying mechanisms of appetite regulation and metabolic disorders. -
Melatonin Agonist
UCM 608 is a high-affinity agonist of melatonin (MT) receptors, specifically targeting MT1 and MT2 with pKi values of 10.7 and 10.4, respectively. This compound exhibits significant biological activity in modulating melatonin signaling pathways, making it valuable for research applications related to sleep regulation, circadian rhythm studies, and potential therapeutic interventions for sleep disorders. -
Melatonin Receptor Agonist
N-Acetyltryptamine is a partial agonist for melatonin receptors, particularly in retinal tissues. It plays a crucial role in modulating circadian rhythms and has applications in studying melatonin signaling pathways. Additionally, N-Acetyltryptamine is utilized to assess serotonin N-acetyl transferase activity in biochemical research. -
Melatonin Receptor Antagonist
S-20928 is a selective antagonist of melatonin receptors, inhibiting melatonin’s binding to these receptors. This compound has been demonstrated to enhance the 2-Deoxy-D-glucose (2DG)-induced elevation of blood glucose and glucagon levels in rat brain studies. S-20928 is relevant for research on metabolic regulation and the physiological effects of melatonin modulation. -
Melatonin Receptor Agonist
Melatonin Receptor Agonist 1 is a selective agonist for the melatonin receptors, specifically showing Ki values of 108 nM for MT2 and 1140 nM for MT1. This compound is useful for studying melatonin signaling pathways and their roles in various physiological processes, including sleep regulation and circadian rhythm modulation. Its potential applications in research extend to areas such as neurobiology, sleep disorders, and the effects of melatonin on metabolic processes. -
Melatonin Receptor Agonist
6-Chloromelatonin is a highly effective melatonin receptor agonist that exhibits enhanced metabolic stability compared to melatonin. It demonstrates strong binding affinity to the MT1 receptor, competing with both [3H]-melatonin and 2-[125I]-iodomelatonin (pKi = 8.9 and 9.1, respectively). Additionally, 6-Chloromelatonin shows significant competition for [3H]-melatonin binding at MT2 receptors with a pKi value of 9.77. This compound is valuable for research in sleep regulation, circadian rhythms, and neuropharmacology. -
Melatonin Receptor Agonist
GR 196429 is a melatonin receptor agonist primarily targeting the MT1 subtype. This compound has been shown to promote sleep and modify circadian rhythms, in addition to stimulating melatonin release in murine models. It serves as a valuable tool for investigating sleep disorders and the biological mechanisms underlying circadian regulation. -
Inactive Isomer of Melatonin Receptor
(R)-Ramelteon is an orally active compound that serves as an inactive isomer of melatonin receptors 1 and 2. It has been studied for its potential role in modulating sleep patterns and may provide insight into the mechanisms underlying sleep regulation. This compound is of particular interest in research applications related to sleep disorders and circadian rhythm studies. -
Melatonin Receptor Antagonist
GR 128107 is a competitive antagonist of melatonin receptors, exhibiting a high binding affinity with a pKi of 9.6. This compound is utilized in research to investigate the physiological roles of melatonin signaling pathways and its involvement in circadian rhythm regulation. GR 128107 can aid in the exploration of sleep disorders, neurodegenerative diseases, and the modulation of various neurochemical processes. -
Melatonin Receptor Agonist
Nedemelteon is a melatonin receptor agonist that selectively binds to MT1 and MT2 receptors, playing a crucial role in regulating circadian rhythms and sleep-wake cycles. Its primary biological activity includes promoting sleep onset and improving sleep quality, making it valuable for research on sleep disorders and related conditions. This compound is utilized in studies investigating the therapeutic potential of melatonin modulation in various neurological and psychological contexts. -
Melatonin Receptor
Pareptide monohydrochloride is a stable analogue of melanotropin-inhibiting factor (MIF) that primarily targets melatonin receptors. This compound exhibits significant biological activity in modulating melatonin signaling pathways, making it a valuable tool for research in circadian rhythms and sleep disorders. Its application spans various studies focused on neurobiology, pharmacology, and the mechanisms of sleep regulation. -
mGluR5 Negative Allosteric Modulator
VU0477573, a partial negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), demonstrates brain penetrance and engages in neuroprotective and anxiolytic activities. This compound is of significant interest in the research of neurological disorders, including Parkinson's disease, providing insights into potential therapeutic strategies targeting mGluR5. -
mGlu7 Modulator
VU6010608 is a negative allosteric modulator of the metabotropic glutamate receptor 7 (mGlu7), with an IC50 value of 0.76 μM, and effectively crosses the blood-brain barrier. This compound has been shown to inhibit long-term potentiation (LTP) of Schaffer-collateral CA1 synapses in mouse brain slices induced by high-frequency stimulation. VU6010608 is suitable for research applications investigating neurological disorders and the modulation of synaptic plasticity. -
mGluR1/5 Agonist
DHPG is a potent agonist for metabotropic glutamate receptors mGluR1 and mGluR5, with an EC50 of 60 nM for mGluR1. Its activation triggers the phospholipase C (PLC) signaling pathway, subsequently activating protein kinase C (PKC). DHPG is widely utilized in research to explore synaptic transmission, neuroplasticity, and the therapeutic potential of targeting mGluR signaling in neurological disorders. -
mGluRs Positive Allosteric Modulator
VU0422288 is a positive allosteric modulator of group III metabotropic glutamate receptors (mGluRs). It demonstrates inhibitory activity with EC50 values of 125 nM, 146 nM, and 108 nM for mGluR4, mGluR7, and mGluR8, respectively, as established in calcium mobilization assays. This compound has potential applications in addressing deficits in contextual fear memory, social recognition, and apneas in models of Rett syndrome. -
mGluR1a Antagonist
LY367385 hydrochloride is a selective antagonist of the metabotropic glutamate receptor 1a (mGluR1a). It exhibits a potent inhibitory effect on quisqualate-induced phosphoinositide hydrolysis, with an IC50 value of 8.8 μM. This compound has demonstrated neuroprotective properties and exhibits anticonvulsant and antiepileptic effects, making it valuable for research in neurological disorders and related pharmacological studies. -
mGluR7 Antagonist
MMPIP hydrochloride is a selective allosteric antagonist of the metabotropic glutamate receptor 7 (mGluR7) with KB values ranging from 24 to 30 nM. It serves as a valuable pharmacological tool for investigating the role of mGluR7 in central nervous system functions. Research indicates that MMPIP hydrochloride can alleviate pain and restore normative affective and cognitive behaviors in models of neuropathic pain. -
mGluR Activator
Quisqualic acid is a potent mGluR (metabotropic glutamate receptor) activator derived from the natural source Quisqualis indica. As an excitatory amino acid agonist, it exhibits significant potency with an EC50 of 45 nM and a Ki of 10 nM for mGluR1R. This compound is valuable for research applications involving neurological studies, receptor signaling pathways, and the exploration of excitatory neurotransmission mechanisms.
